BPX-601

PSCA-targeted chimeric antigen receptor T cell therapy · Regeneron Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BPX-601, covering 2026-02-23 to 2026-02-23. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors [Phase 1]

See pricing